z-logo
Premium
Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells
Author(s) -
Stucki Anne,
Hayflick Joel S.,
Sandmaier Brenda M.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.01811.x
Subject(s) - microbiology and biotechnology , myeloid , biology , haematopoiesis , cell adhesion molecule , intercellular adhesion molecule 1 , apoptosis , lymphocyte , cd11a , antibody , monoclonal antibody , chemistry , immunology , cd18 , stem cell , biochemistry
Intercellular adhesion molecule 3 (ICAM‐3, CD50) is an immunoglobulin (Ig) domain‐containing cell–cell adhesion receptor that binds to the lymphocyte function antigen 1 (LFA‐1; CD11a/CD18) integrin. It is constitutively expressed on haematopoietic precursors and differentiated leucocytes, as well as on most leukaemic cells. ICAM‐3/LFA‐1 binding during a lymphocyte‐mediated cellular immune response has been well established; however, its role in the marrow compartment is unclear. In this study, marrow cells from normal and acute leukaemic donors, as well as leukaemic cell lines, were cultured in the presence of various monoclonal antibodies (mAbs) to ICAM‐3, and apoptosis was subsequently measured by annexin V binding. Anti‐ICAM‐3 mAb ICR 1.1 engagement triggered increased percentages of apoptosis among normal and leukaemic marrow myeloid cells. Fab fragments of ICR 1.1 mimicked the intact mAb, suggesting that the apoptotic signal was independent of Fc receptor interactions and did not require bivalent epitope engagement. In addition, the apoptotic signal was found to be independent of ICAM‐1/LFA‐1 binding interactions, as well as Fas/FasL and tumour necrosis factor alpha (TNF‐α)/TNF receptor‐activated pathways, as neutralizing antibodies to CD11a/CD18, Fas and TNF‐α failed to abrogate the response.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here